TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27094721

Group type: EXPERIMENTAL
Intervention: d-cycloserine (DCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: modafinil
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 24345165

Group type: EXPERIMENTAL
Intervention: D2/D3 dopamine receptor binding measured using [F-18]fallypride
Number of subjects: 0
Study: 21972884

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 84
Study: 19653485

Group type: EXPERIMENTAL
Intervention: Spatialized voices augmented by a visual display of relative talker locations
Number of subjects: 50

Group type: COMPARATOR
Intervention: Spatialized voices with an audio-only display
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonspatialized voices with an audio-only display
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Spatialized voices with large-angle displays
Number of subjects: 50
Study: 17726460

Group type: EXPERIMENTAL
Intervention: Mouse TYR DNA vaccine followed by human TYR DNA vaccine (3 injections each, 100, 500, and 1,500 microg DNA/injection, IM every 3 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Human TYR DNA vaccine followed by mouse TYR DNA vaccine (3 injections each, 100, 500, and 1,500 microg DNA/injection, IM every 3 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both mouse and human TYR DNA vaccines
Number of subjects: 18
Study: 15241748

Group type: EXPERIMENTAL
Intervention: Home-based physical therapy (PT) program (prehabilitation)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Educational control group
Number of subjects: 188
Study: 11756645

Group type: EXPERIMENTAL
Intervention: Natural L-glutamine (0.5 g x kg(‐1) x d(‐1))
Number of subjects: 13
Study: 10633487

Group type: EXPERIMENTAL
Intervention: Low dose haloperidol
Number of subjects: 20
Study: 8624062

Group type: EXPERIMENTAL
Intervention: Impedance planimetry
Number of subjects: 24
Study: 1478512

Group type: EXPERIMENTAL
Intervention: Diazepam (Group A, n = 19)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Magnesium sulfate (Group B, n = 19)
Number of subjects: 38
Study: 6716120

Group type: EXPERIMENTAL
Intervention: Lower lip perturbations (1 mm and 15 mm loads) during speech gestures
Number of subjects: 0
Study: 31029989

Group type: EXPERIMENTAL
Intervention: TLIP block combined with general anesthesia (T group, n=35)
Number of subjects: 72

Group type: COMPARATOR
Intervention: General anesthesia alone (C group, n=34)
Number of subjects: 72
Study: 29995462

Group type: EXPERIMENTAL
Intervention: Balance-training protocol
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Strength-training protocol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (mild to moderately strenuous bicycle workout)
Number of subjects: 39
Study: 27587519

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Epidural Analgesia (PCEA)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Local Infiltration Analgesia (LIA)
Number of subjects: 222
Study: 25228838

Group type: EXPERIMENTAL
Intervention: Vitamin D group (cholecalciferol 2,000 IU/day + calcium 200 mg/day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo group (calcium 200 mg/day)
Number of subjects: 81
Study: 21651747

Group type: EXPERIMENTAL
Intervention: Six supervised supplemental exercise sessions
Number of subjects: 118

Group type: COMPARATOR
Intervention: Three follow-up examinations without exercise (Control)
Number of subjects: 118
Study: 20097928

Group type: EXPERIMENTAL
Intervention: 4-strand hamstring autograft (HAM)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Patellar tendon-bone autograft (PTB)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Uninvolved knee (HAM)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Uninvolved knee (PTB)
Number of subjects: 72
Study: 17646243

Group type: EXPERIMENTAL
Intervention: Running group (training 3 times/week, 60 min each for 6 months)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cycling group (training 3 times/week, 90 min each for 6 months)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 21
Study: 15980691

Group type: EXPERIMENTAL
Intervention: Coformulated zidovudine/lamivudine/abacavir (group 1)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Coformulated zidovudine/lamivudine plus nevirapine (group 2)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 134
Study: 12627304

Group type: COMPARATOR
Intervention: Strength training only (S)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Concurrent strength and endurance training (SE)
Number of subjects: 27
Study: 11783186

Group type: EXPERIMENTAL
Intervention: Neiyi 1+ pill (TCM group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Tamoxifen (control group)
Number of subjects: 45
Study: 8724034

Group type: EXPERIMENTAL
Intervention: Triple combination (loviride + lamivudine + zidovudine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Double combination (loviride + zidovudine)
Number of subjects: 20
Study: 1750290

Group type: EXPERIMENTAL
Intervention: Pump-driven hemofiltration (PDHF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spontaneous hemofiltration
Number of subjects: 0
Study: 30010698

Group type: EXPERIMENTAL
Intervention: Resistant starch (RS2) 45 g/d for 12 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (isocaloric amount of rapidly digestible starch amylopectin)
Number of subjects: 68
Study: 27087153

Group type: EXPERIMENTAL
Intervention: 0.005 mg/kg cisatracurium
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg cisatracurium
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg cisatracurium
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no cisatracurium)
Number of subjects: 90
Study: 24660759

Group type: EXPERIMENTAL
Intervention: EMD/FDBA (EF)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: EMD/DFDBA (ED)
Number of subjects: 69

Group type: COMPARATOR
Intervention: EMD alone (E)
Number of subjects: 69
Study: 22863299

Group type: EXPERIMENTAL
Intervention: Case finding and collaborative care
Number of subjects: 162

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 162
Study: 19918186

Group type: EXPERIMENTAL
Intervention: 720 ms duration Italian word presented 80 times; signals from 16 electrodes were averaged and displayed as traces and maps.
Number of subjects: 36

Group type: COMPARATOR
Intervention: 300 Hz tone of the same duration (720 ms); signals from 16 electrodes were averaged and displayed as traces and maps.
Number of subjects: 36
Study: 17989152

Group type: EXPERIMENTAL
Intervention: Aerosolized salbutamol (5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nebulization of ipratropium bromide (0.5 mg)
Number of subjects: 24
Study: 15309429

Group type: EXPERIMENTAL
Intervention: Rice bran oil (RBO) with low gamma-oryzanol (0.05 g/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rice bran oil (RBO) with high gamma-oryzanol (0.8 g/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Peanut oil (PNO) during run-in period
Number of subjects: 30
Study: 11873027

Group type: EXPERIMENTAL
Intervention: Paresthesia technique using insulated or noninsulated needle connected to a peripheral nerve stimulator (power off)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulator turned on at the point of paresthesia
Number of subjects: 30
Study: 10073603

Group type: EXPERIMENTAL
Intervention: Increased IL-13 mRNA expression in CD4+ and CD8+ T cells during nephrotic relapse compared to remission, normal, and patient controls (P < 0.008).
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Increased cytoplasmic IL-13 expression in phorbol myristate acetate/ionomycin-activated CD3+ cells from patients with nephrotic relapse (6.66+/‐3.39%) compared to remission (2.59+/‐1.35%) (P < 0.0001).
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: No significant difference in CD4+ or CD8+ IL-2, interferon-gamma, and IL-4 mRNA expression.
Number of subjects: 55
Study: 7577887

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 25 ng/min per kg ideal body weight for 90 min after fasting for 12, 36, and 72 hours
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion
Number of subjects: 9
Study: 2040935

Group type: EXPERIMENTAL
Intervention: Aztreonam-arginine plus ampicillin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gentamicin plus ampicillin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 7259326

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion at a dose of 6‐10 ng/kg/min for 72 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 12
Study: 31089768

Group type: EXPERIMENTAL
Intervention: PZQ + KTZ (20 mg/kg PZQ + 200 mg ketoconazole)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PZQ alone (20 mg/kg)
Number of subjects: 0
Study: 28368549

Group type: EXPERIMENTAL
Intervention: Take a Stand! intervention
Number of subjects: 317

Group type: COMPARATOR
Intervention: Control group (usual behavior)
Number of subjects: 317
Study: 26907933

Group type: EXPERIMENTAL
Intervention: Bimatoprost Unit Dose Preservative Free (BUDPF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latanoprost Unit Dose Preservative Free (LUDPF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BUDPF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LUDPF
Number of subjects: 0
Study: 24067348

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 410

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 410
Study: 22655047

Group type: EXPERIMENTAL
Intervention: Multidisciplinary Integrated Care (MIC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 10
Study: 19101664

Group type: EXPERIMENTAL
Intervention: Resistance-training program
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 16645458

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 0.0005% epinephrine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Preservative‐free saline
Number of subjects: 80
Study: 12499320

Group type: COMPARATOR
Intervention: 4 g EPA+DHA (4:0)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 4 g EPA+DHA plus 1 g GLA (4:1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 2 g GLA (4:2)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 4 g GLA (4:4)
Number of subjects: 31
Study: 10820352

Group type: EXPERIMENTAL
Intervention: Transvaginal color Doppler ultrasound (TV‐CDU)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Serum SCC levels
Number of subjects: 88
Study: 8869688

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg/day for 3 days)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Prednisolone (50 mg/day for 3 days)
Number of subjects: 109
Study: 1531552

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 256

Group type: COMPARATOR
Intervention: Continued treatment by the general practitioner
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo therapy (detuned ultrasound and detuned short‐wave diathermy)
Number of subjects: 256
Study: 6360749

Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetysalicylic acid (ASA)
Number of subjects: 0
Study: 31074823

Group type: EXPERIMENTAL
Intervention: Ustekinumab therapy for 8 weeks or more
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Prediction model using week-6 albumin to CRP ratio
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Week-8 model
Number of subjects: 401
Study: 28658582

Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (10 mg.kg‐1 body mass of sodium nitrate)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nitrate supplementation
Number of subjects: 11
Study: 25239019

Group type: EXPERIMENTAL
Intervention: Complex multidisciplinary intervention (GNS-led staff education, facility benchmarking, GNS resident review, multidisciplinary discussions) for 9 months
Number of subjects: 1998

Group type: EXPERIMENTAL
Intervention: Complex multidisciplinary intervention
Number of subjects: 1998

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1998
Study: 23388533

Group type: EXPERIMENTAL
Intervention: Cycloferon (in tablets) administered under standard regimen to frequently ill children (FIC)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group of frequently ill children (FIC)
Number of subjects: 250
Study: 21756323

Group type: COMPARATOR
Intervention: Metformin 850 mg bid (n = 42)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg bid (n = 40)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Combination of pioglitazone 30 mg and metformin 1.7 g (n = 39)
Number of subjects: 121
Study: 19371961

Group type: EXPERIMENTAL
Intervention: Time Encoded Signal Processing And Recognition (TESPAR) technique combined with multi-layer perceptrons for DOA estimation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TESPAR technique
Number of subjects: 0
Study: 16828598

Group type: EXPERIMENTAL
Intervention: SC plus nesiritide 0.005 microg/kg/min
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: SC plus nesiritide 0.010 microg/kg/min
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 138
Study: 14679315

Group type: EXPERIMENTAL
Intervention: Soy-based milk and yoghurt (treatment)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Equivalent dairy products (control)
Number of subjects: 26
Study: 11532479

Group type: EXPERIMENTAL
Intervention: IN/hMG
Number of subjects: 379

Group type: COMPARATOR
Intervention: SC/FSH
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: SC/hMG
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: IN/FSH
Number of subjects: 379
Study: 9760639

Group type: EXPERIMENTAL
Intervention: Specific + Variable
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Specific + Varplus
Number of subjects: 75

Group type: COMPARATOR
Intervention: Specific
Number of subjects: 75
Study: 8138776

Group type: EXPERIMENTAL
Intervention: Health Measurement Questionnaire (HMQ)
Number of subjects: 430

Group type: COMPARATOR
Intervention: General Health Questionnaire (GHQ)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Nottingham Health Profile (NHP)
Number of subjects: 430
Study: 2899663

Group type: EXPERIMENTAL
Intervention: Feverfew (one capsule of dried feverfew leaves a day for four months)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (matching placebo for four months)
Number of subjects: 72
Study: 30575345

Group type: EXPERIMENTAL
Intervention: Drug therapy (Group 1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Surgical treatment (Group 2)
Number of subjects: 32
Study: 27470681

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TA) 1 g loading dose followed by 1 g over 8 hours
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous 0.9% normal saline (placebo)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TA)
Number of subjects: 66
Study: 25694536

Group type: EXPERIMENTAL
Intervention: Repeat pulmonary vein isolation (PVI)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: PVI with an additional left atrial anterior line
Number of subjects: 77

Group type: COMPARATOR
Intervention: PVI
Number of subjects: 77

Group type: COMPARATOR
Intervention: PVI + anterior line
Number of subjects: 77
Study: 23564052

Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound (HIFU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional Myomectomy (MYG)
Number of subjects: 100
Study: 20681234

Group type: EXPERIMENTAL
Intervention: Level Walking (LW)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Downhill Walking (DW)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both LW and DW
Number of subjects: 10
Study: 18194526

Group type: EXPERIMENTAL
Intervention: Graded task with action planning
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Persuasive communication
Number of subjects: 340

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 340
Study: 17187695

Group type: EXPERIMENTAL
Intervention: CCE booklet
Number of subjects: 308

Group type: COMPARATOR
Intervention: AZ booklet
Number of subjects: 308
Study: 15125484

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, p.o.)
Number of subjects: 24
Study: 11151233

Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C (MMC) 0.2 mg/ml for 2 minutes
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no MMC)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C (MMC)
Number of subjects: 17
Study: 9074367

Group type: EXPERIMENTAL
Intervention: High vacuum drainage system
Number of subjects: 141

Group type: COMPARATOR
Intervention: Low vacuum drainage system
Number of subjects: 141
Study: 8020029

Group type: EXPERIMENTAL
Intervention: Untreated atrial fibrillation (AF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk stratification for thromboembolism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recent onset AF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Underlying heart disease
Number of subjects: 0
Study: 3623744

Group type: EXPERIMENTAL
Intervention: Dapsone (DDS) 100 mg orally in dogs
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dapsone (DDS) 100 mg intravenously in dogs
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dapsone (DDS) 50 mg intravenously in healthy volunteers
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dapsone (DDS) 50 mg orally in healthy volunteers
Number of subjects: 10
Study: 30100314

Group type: EXPERIMENTAL
Intervention: Postural insoles with corrective elements for equinovarus foot
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo insoles with no corrective elements
Number of subjects: 20
Study: 27598379

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) technique, performed daily over eight weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 40
Study: 24119823

Group type: EXPERIMENTAL
Intervention: 40 mg of methylphenidate (MPH)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 mg of levodopa (LEV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 30
Study: 22669008

Group type: EXPERIMENTAL
Intervention: Silicone elastomer (SE) contact lenses
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Rigid gas permeable (RGP) contact lenses
Number of subjects: 57
Study: 19596580

Group type: EXPERIMENTAL
Intervention: Hemicellulose dressing
Number of subjects: 28

Group type: COMPARATOR
Intervention: Rayon dressing
Number of subjects: 28
Study: 17846935

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (PcV) for five days
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (PcV)
Number of subjects: 179

Group type: COMPARATOR
Intervention: No primary antibiotic treatment
Number of subjects: 179
Study: 15378235

Group type: EXPERIMENTAL
Intervention: Nonsurgical radiofrequency energy (RF) tissue micro-remodeling
Number of subjects: 41
Study: 12586130

Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/day
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/day and warfarin (INR 2.0-2.5)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Warfarin (INR 2.8-4.2)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Aspirin groups combined (n=129)
Number of subjects: 202
Study: 9824878

Group type: EXPERIMENTAL
Intervention: Enhanced verbal instruction
Number of subjects: 32

Group type: COMPARATOR
Intervention: Monetary reinforcement (high vs. low)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard instructions (control group)
Number of subjects: 32
Study: 7916881

Group type: EXPERIMENTAL
Intervention: Rhine fish consumption
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (no Rhine fish)
Number of subjects: 149
Study: 2086257

Group type: EXPERIMENTAL
Intervention: Titanol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitinol
Number of subjects: 20
Study: 907396

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Truncal vagotomy with antrectomy (TV + A)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Selective gastric vagotomy with Finney pyloroplasty (SGV + P)
Number of subjects: 174
Study: 30980315

Group type: EXPERIMENTAL
Intervention: Subterranean pulmonary rehabilitation (Group I)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Surface pulmonary rehabilitation (Group II)
Number of subjects: 42
Study: 28846767

Group type: EXPERIMENTAL
Intervention: 50 µg/d transdermal 17β‐estradiol (t‐E2)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: 0.45 mg/d oral conjugated equine estrogens (o‐CEE)
Number of subjects: 670

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 670
Study: 25962988

Group type: EXPERIMENTAL
Intervention: C-arm computed tomography (CT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 50
Study: 23537605

Group type: EXPERIMENTAL
Intervention: Community Treatment Orders (CTOs)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Section 17 leave
Number of subjects: 333
Study: 21784215

Group type: EXPERIMENTAL
Intervention: Experimental group 1 (EG1) - taught using pictograms in the clinic
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Experimental group 2 (EG2) - taught using pictograms in the clinic and given pictograms to take home
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group - given verbal instruction only
Number of subjects: 225
Study: 20205551

Group type: EXPERIMENTAL
Intervention: NeuroPage system
Number of subjects: 12
Study: 16197583

Group type: EXPERIMENTAL
Intervention: 30 g isomalt daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: 30 g sucrose daily (Control)
Number of subjects: 19
Study: 14612516

Group type: EXPERIMENTAL
Intervention: HPV16 positive individuals
Number of subjects: 85